Kiadis Pharma and the Leukemia & Lymphoma Society Enter Partnership for the Development of ATIR101™ in ALL …
AMSTERDAM--(BUSINESS WIRE)--Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”)
(Euronext Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company developing innovative T-cell immunotherapy
treatments for blood cancers and inherited blood disorders, today
announces that it has entered into a partnership with The Leukemia
Lymphoma Society (LLS) under which LLS will fund the Phase II
development of Kiadis Pharma’s lead product, Read more [...]